Molecular aspects of antitumor effects of a new platinum(IV) drug

Molecular Pharmacology

Volumn 70, Issue 5, 2006, Pages 1708-1719

  Kašpárková, Jana ^a   Nováková, Olga ^a   Vrána, Oldřich ^a   Intini, Francesco ^b   Natile, Giovanni ^b   Brabec, Viktor ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMPLATIN IV; ASCORBIC ACID; CISPLATIN; GLUTATHIONE; HIGH MOBILITY GROUP PROTEIN; METALLOTHIONEIN; PLATINUM; PLATINUM IV; SULFUR DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPARATIVE STUDY; DNA MODIFICATION; DNA REPAIR; DNA SYNTHESIS; DRUG ACCUMULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CROSS LINKING; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; BASE SEQUENCE; CELL LINE, TUMOR; CELL-FREE SYSTEM; CROSS-LINKING REAGENTS; DNA; DNA ADDUCTS; DNA REPAIR; DNA-DIRECTED RNA POLYMERASES; HELA CELLS; HIGH MOBILITY GROUP PROTEINS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PLASMIDS; PLATINUM; RATS; RNA-DIRECTED DNA POLYMERASE; SULFUR COMPOUNDS; VIRAL PROTEINS;

EID: 33751182358     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.027730     Document Type: Article

References (48)

1. Bancroft DP, Lepre CA, and Lippard SJ (1990) Pt-195 NMR kinetic and mechanistic studies of cis-diamminedichloroplatinum and trans- diamminedichloroplatinum(II) binding to DNA. J Am Chem Soc 112:6860-6871.
2. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, and Ozols RF (1987) Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47:414-418.
3. Boudny V, Vrana O, Gaucheron F, Kleinwächter V, Leng M, and Brabec V (1992) Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. Nucleic Acids Res 20:267-272.
4. Brabec V (2000) Chemistry and structural biology of 1,2-interstrand adducts of cisplatin, in Platinum-Based Drugs in Cancer Therapy (Kelland LR and Farrell NP eds) pp 37-61, Humana Press, Inc., Totowa, NJ.
5. Brabec V (2002) DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog Nucleic Acid Res Mol Biol 71:1-68.
6. Brabec V and Kasparkova J (2005) Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updates 8:131-146.
7. Brabec V, Kasparkova J, Vrana O, Novakova O, Cox JW, Qu Y, and Farrell N (1999) DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent. Biochemistry 38:6781-6790.
8. Brabec V and Leng M (1993) DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc Natl Acad Sci USA 90:5345-5349.
9. Brabec V and Palecek E (1976) Interaction of nucleic acids with electrically charged surfaces. II. Conformational changes in double-helical polynucleotides. Biophys Chem 4:76-92.
10. Brabec V, Reedijk J, and Leng M (1992) Sequence-dependent distortions induced in DNA by monofunctional platinum(II) binding. Biochemistry 31:12397-12402.
11. 2]. Nucleic Acids Res 24:336-341.
12. Farrell N, Povirk LF, Dange Y, DeMasters G, Gupta MS, Kohlhagenc G, Khanc QA, Pommier Y, and Gewirtz DA (2004) Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells. Biochem Pharmacol 68:857-866.
13. Fuertes MA, Alonso C, and Perez JM (2003) Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 103:645-662.
14. Giandomenico CM, Abrams MJ, Murrer BA, Vollano JF, Rheinheimer MI, Wyer SB, Bossard GE, and Higgins JD (1995) Carboxylation of kinetically inert platinum(IV) hydroxy complexes-an entree into orally-active platinum(IV) antitumor agents. Inorg Chem 34:1015-1021.
15. Hagrman D, Goodisman J, Dabrowiak JC, and Souid AK (2003) Kinetic study on the reaction of cisplatin with metallothionein. Drug Metab Dispos 31:916-923.
16. Hall MD and Hambley TW (2002) Platinum(IV) antitumour compounds: their bioinorganic chemistry. Coord Chem Rev 232:49-67.
17. 2, a metabolite of an orally active platinum anticancer drug. J Am Chem Soc 114:5646-5654.
18. He Q, Ohndorf U-A, and Lippard SJ (2000) Intercalating residues determine the mode of HMG1 domains A and B binding to cisplatin-modified DNA. Biochemistry 39:14426-14435.
19. Intini FP, Boccarelli A, Francia VC, Pacifico C, Sivo MF, Natile G, Giordano D, De Rinaldis P, and Coluccia M (2004) Platinum complexes with imino ethers or cyclic ligands mimicking imino ethers: synthesis, in vitro antitumour activity, and DNA interaction properties. J Biol Inorg Chem 9:768-780.
20. Johnson NP, Butour J-L, Villani G, Wimmer FL, Defais M, Pierson V, and Brabec V (1989) Metal antitumor compounds: the mechanism of action of platinum complexes. Prog Clin Biochem Med 10:1-24.
21. Kasparkova J, Farrell N, and Brabec V (2000) Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes. J Biol Chem 275:15789-15798.
22. Kasparkova J, Novakova O, Marini V, Najajreh Y, Gibson D, Perez J-M, and Brabec V (2003a) Activation of trans geometry in bifunctional mononuclear platinum complexes by a piperidine ligand: mechanistic studies on antitumor action. J Biol Chem 278:47516-47525.
23. Kasparkova J, Novakova O, Najajreh Y, Gibson D, Perez J-M, and Brabec V (2003b) Effects of a piperidine ligand on the mechanism of action of antitumor cisplatin. Chem Res Toxicol 16:1424-1432.
24. Kelland LR (2000) New platinum drugs. The pathway to oral therapy, in Platinum-Based Drugs in Cancer Therapy (Kelland LR and Farrell NP eds) pp 299-319, Humana Press, Inc., Totowa, NJ.
25. Kim SD, Vrana O, Kleinwächter V, Niki K, and Brabec V (1990) Polarographic determination of subnanogram quantities of free platinum in reaction mixture with DNA. Anal Lett 23:1505-1518.
26. Kozubík A, Horvath V, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, Kroutil A, Zak F, Mistr A, and Turanek J (2005) High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem Pharmacol 69:373-383.
27. Lambert B, Jestin JL, Brehin P, Oleykowski C, Yeung AT, Mailliet P, Pretot C, Lepecq JB, Jacqueminsablon A, and Chottard JC (1995) Binding of the Escherichia coli UvrAB proteins to the DNA mono- and diadducts of cis-[N-2-amino-N-2-methylamino-2,2,1-bicycloheptane]dichloroplatinum(II) and cisplatin-analysis of the factors controlling recognition and proof of monoadduct-mediated UvrB-DNA cross-linking. J Biol Chem 270:21251-21257.
28. Lemma K, Sargeson AM, and Elding LI (2000) Kinetics and mechanism for reduction of oral anticancer platinum(IV) dicarboxylate compounds by L-ascorbate ions. J Chem Soc Dalton Trans 7:1167-1172.
29. Malina J, Kasparkova J, Natile G, and Brabec V (2002) Recognition of major DNA adducts of enantiomeric cisplatin analogs by HMG box proteins and nucleotide excision repair of these adducts. Chem Biol 9:629-638.
30. Marini V, Christofis P, Novakova O, Kasparkova J, Farrell N, and Brabec V (2005) Conformation, protein recognition and repair of DNA interstrand and intrastrand cross-links of antitumor trans-[PtCl2(NH3)(thiazole)]. Nucleic Acids Res 33:5819-5828.
31. Moeller N, Kangarloo BS, Puscasu I, Mock C, Krebs B, and Wolff JEA (2000) Rational design of platinum chemotherapeutic drugs: hydrophobicity increases cytotoxicity. Anticancer Res 20:4435-4439.
32. Novakova O, Kasparkova J, Bursova V, Hofr C, Vojtiskova M, Chen H, Sadler PJ, and Brabec V (2005) Conformation of DNA modified by monofunctional Ru(II) arene complexes: recognition by DNA-binding proteins and repair. Relationship to cytotoxicity. Chem Biol 12:121-129.
33. 2]. A concept for activation of the trans geometry in platinum antitumor complexes. Nucleic Acids Res 31:6450-6460.
34. O'Neill CF, Koberle B, Masters JRW, and Kelland LR (1999) Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br J Cancer 81:1294-1303.
35. Page JD, Husain I, Sancar A, and Chaney SG (1990) Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 29:1016-1024.
36. Plooy ACM, Van Dijk M, and Lohman PHM (1984) Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res 44:2043-2051.
37. Reardon JT, Vaisman A, Chaney SG, and Sancar A (1999) Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine- dichlorocyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59:3968-3971.
38. Reedijk J (1999) Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem Rev 99:2499-2510.
39. Romero-Isart N and Vasak M (2002) Advances in the structure and chemistry of metallothioneins. J Inorg Biochem 88:388-396.
40. Shiozaki A, Yamagishi H, Itoi H, Fujiwara H, Kikuchi S, Okamoto K, Ichikawa D, Fuji N, Ochiai T, Sonoyama T, et al. (2005) Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer. Oncol Rep 13:667-672.
41. Stros M (2001) Two mutations of basic residues within the N-terminus of HMG-1 B domain with different effects on DNA supercoiling and binding to bent DNA. Biochemistry 40:4769-4779.
42. Turanek J, Kasna A, Zaluska D, Neca J, Kvardova V, Knotigova P, Horvath V, Sindlerova L, Kozubik A, Sova P, et al. (2004) New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes. Anticancer Drugs 15:537-543.
43. Wei M, Burenkova O, and Lippard SJ (2003) Cisplatin sensitivity in Hmgb1(-/-) and Hmgb1 mouse cells. J Biol Chem 278:1769-1773.
44. Wei M, Cohen SM, Silverman AP, and Lippard SJ (2001) Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins. J Biol Chem 276:38774-38780.
45. Zamble DB and Lippard SJ (1999) The response of cellular proteins to cisplatin-damaged DNA, in Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug (Lippert B ed) pp 73-110. Wiley-VCH, Zürich, Switzerland.
46. Zehnulova J, Kasparkova J, Farrell N, and Brabec V (2001) Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464. J Biol Chem 276:22191-22199.
47. Zhitkovich A and Costa M (1992) A simple, sensitive assay to detect DNA-protein crosslinks in intact cells and in vivo. Carcinogenesis 13:1485-1489.
48. Zhong W, Zhang Q, Yan Y, Yue S, Zhang B, and Tang W (1997) Reaction of a platinum(IV) complex with native Cd, Zn-metallothionein in vitro. J Inorg Biochem 66:179-185.